Providers need to be able to prepare patients to start buprenorphine therapy, titrate the dose, and establish a final dose. Chapter 4 of TIP 401, later guidelines2,3, and the FSMB Model policy4 describe this process in detail.
The FDA has produced an Appropriate Use checklist to follow for each patient that helps you make sure you follow the REMS guidelines for the medication with each patient.5 Items in the checklist pertaining to induction are explained in this training.
Knowledge gaps are among the main barriers associated with low utilization of OUD medications and this module aims to help address those gaps.6
